8
am -
7
pm ET,
Monday
-
Friday
Phone
1-833-256-2748

Frequently Asked Questions (FAQs)

What is Alnylam AssistTM?

Alnylam Assist is a team of dedicated Case Managers, Patient Education Liaisons, and Field Reimbursement Directors who provide support to patients prescribed Alnylam therapies. These services include: verification of insurance benefits, financial assistance support for eligible patients, disease education, and reimbursement education. Each member of our team is assigned to specific geographic regions to work with patients, their caregivers, family members, healthcare providers, and insurance companies to support the patient in his or her treatment on ONPATTROTM (patisiran).

How do I enroll my patients in the Alnylam Assist program?

There are three ways to enroll your patients:

  • 1. Complete the electronic Start Form
    • You will receive an auto-generated confirmation after submission to let you know we have received the Start Form and are initiating services
    • You and your patient will each receive a phone call from his or her case manager within 1-2 business days of receipt
  • 2. Download and complete the writable PDF version and fax the completed Start Form to Alnylam Assist at 833-256-2747
    • You and your patient will receive a phone call from his or her Case Manager within 1-2 business days of receipt
  • 3. Begin filling out the DocuSign form and email it to your patient to complete
    • Once you have finished your portion of the Start Form and provided an eSignature, it will be emailed to your patient so they can verify his or her information and fill out any remaining fields
    • Both you and your patient will receive notification via email when the completed Start Form has been submitted to Alnylam Assist
    • A Case Manager dedicated to your patient’s needs will reach out to you and your patient within 1-2 business days of receiving the completed Start Form

Who are Case Managers?

Case Managers are experienced in helping individuals get started on treatment and providing ongoing support. They will tailor their level of contact based on each individual's personal needs.

What services does Alnylam Assist provide?

Alnylam Assist provides patients with product support services, including:

  • Benefit verification
  • Education about the prior authorization, claims, and appeals processes
  • Financial assistance program enrollment for eligible patients*
  • Disease and product education
  • Facilitation of product orders

*Patients must meet specified eligibility criteria to qualify for assistance. Alnylam reserves the right to make eligibility determinations and to modify or discontinue the program at any time.

Who are Field Reimbursement Directors?

Field Reimbursement Directors (FRDs) are available to provide education about the ONPATTRO reimbursement process.
FRDs will share their knowledge of:

  • ONPATTRO billing and coding requirements
  • Chart documentation requirements
  • Payer requirements

Who are Patient Education Liaisons (PELs)?

PELs have backgrounds in nursing or genetic counseling, and are experienced in educating individuals and their families about matters related to hATTR amyloidosis. PELs can help patients in a variety of ways, including providing disease and product education, connecting patients to additional resources, and answering questions about treatment.

Separator

Discover More

Patient Services

Learn more about how Alnylam Assist supports
patients being treated with ONPATTROTM.

Get the Facts

Forms and Documents

For more information about Alnylam Assist
and treatment with ONPATTRO.

See Materials

Take Action Now1

Take Action Now

Together with your patient (in office)

Initiate then send to patient (over email)

Important Safety Information

Infusion-Related Reactions

Infusion-related reactions (IRRs) have been observed in patients treated with ONPATTROTM (patisiran). In a controlled clinical study, 19% of ONPATTRO-treated patients experienced IRRs, compared to 9% of placebo-treated patients. The most common symptoms of IRRs with ONPATTRO were flushing, back pain, nausea, abdominal pain, dyspnea, and headache.

To reduce the risk of IRRs, patients should receive premedication with a corticosteroid, acetaminophen, and antihistamines (H1 and H2 blockers) at least 60 minutes prior to ONPATTRO infusion. Monitor patients during the infusion for signs and symptoms of IRRs. If an IRR occurs, consider slowing or interrupting the infusion and instituting medical management as clinically indicated. If the infusion is interrupted, consider resuming at a slower infusion rate only if symptoms have resolved. In the case of a serious or life-threatening IRR, the infusion should be discontinued and not resumed. 

Reduced Serum Vitamin A Levels and Recommended Supplementation

ONPATTRO treatment leads to a decrease in serum vitamin A levels. Supplementation at the recommended daily allowance (RDA) of vitamin A is advised for patients taking ONPATTRO. Higher doses than the RDA should not be given to try to achieve normal serum vitamin A levels during treatment with ONPATTRO, as serum levels do not reflect the total vitamin A in the body.

Patients should be referred to an ophthalmologist if they develop ocular symptoms suggestive of vitamin A deficiency (e.g. night blindness).

Adverse Reactions

The most common adverse reactions that occurred in patients treated with ONPATTRO were upper respiratory tract infections (29%) and infusion-related reactions (19%).

Indication

ONPATTRO is indicated for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults.

For additional information about ONPATTRO, please see the full Prescribing Information.